“Vertex: Why We’re Still Bullish Despite Lowered Hopes for Journavx Pain Relief”
Vertex’s Journavx Faces Adoption Challenges Despite FDA Approval for Acute Pain Challenges Ahead Vertex’s Journavx recently received FDA approval for the treatment of acute pain, but the road to widespread adoption may be tougher than expected. The drug faces several challenges, including variable efficacy compared to opioids, generic competition, and entrenched prescriber habits that could…